Could a simple scan reveal the most dangerous form of colon cancer?
NCT ID NCT06191120
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new type of PET/CT scan that uses a radioactive tracer called FAPI to detect an aggressive form of colorectal cancer known as CMS4. The CMS4 subtype is linked to worse outcomes and may not respond well to standard chemotherapy. Researchers will scan 45 patients with colorectal cancer that has spread to the liver, then compare scan results with tissue samples to see if the scan can accurately identify CMS4. If it works, this imaging method could help doctors personalize treatment without needing multiple biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, 3584 CX, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]-ALF-FAPI-74 (a radioactive tracer for PET/CT scans)
What this could lead to
If successful, this scan could provide a non-invasive way to identify the aggressive CMS4 colorectal cancer subtype, helping doctors choose more effective treatments for each patient.
What could go wrong
This is a small early-phase study with only 45 participants, so results may not apply to all patients. The scan's accuracy in detecting CMS4 is still unproven, and it is not yet a standard diagnostic tool.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.